Vimab Group Valuation

Q: What is the Fair Price of VIMAB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

VIMAB (SEK12.5) is trading below our estimate of [[fair value]] (SEK30.67)

Is VIMAB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VIMAB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: VIMAB (SEK12.5) is trading below our estimate of fair value (SEK30.67)

Significantly Below Fair Value: VIMAB is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VIMAB?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for VIMAB. This is calculated by dividing VIMAB's market cap by their current preferred multiple.
What is VIMAB's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	SEK 294.96m

VIMAB key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.2x
Enterprise Value/EBITDA	22.1x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does VIMAB's PS Ratio compare to its peers?

The above table shows the PS ratio for VIMAB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	1.4x
AIXIA B Aixia Group	0.7x	n/a	SEK 241.1m
PENG B Projektengagemang Sweden	0.3x	3.2%	SEK 236.7m
HIFA B Hifab Group	0.6x	n/a	SEK 194.7m
SIBEK Sibek	4x	n/a	SEK 607.2m
VIMAB Vimab Group	0.8x	n/a	SEK 295.0m

Price-To-Sales vs Peers: VIMAB is good value based on its Price-To-Sales Ratio (0.8x) compared to the peer average (1.4x).

Price to Earnings Ratio vs Industry

How does VIMAB's PE Ratio compare vs other companies in the SE Professional Services Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	16.1%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	16.1%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: VIMAB is expensive based on its Price-To-Sales Ratio (0.8x) compared to the European Professional Services industry average (0.8x).

Price to Sales Ratio vs Fair Ratio

What is VIMAB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VIMAB PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.8x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate VIMAB's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.